Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SGN-B6A versus docetaxel in previously treated advanced non-small cell lung cancer
MOH_2024-07-01_013497Phase 3Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- May 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing SGN-B6A with docetaxel (2 arms). Started May 2024; status: active, not recruiting.
02
Drugs
sigvotatug vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-07-01_013497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-01_013497.